Sarah Pereira Gomes, Sofia Rodrigues Lima, Fabio Gomes de Matos Souza, Luísa Weber Bisol
{"title":"Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression","authors":"Sarah Pereira Gomes, Sofia Rodrigues Lima, Fabio Gomes de Matos Souza, Luísa Weber Bisol","doi":"10.1177/02698811241276505","DOIUrl":null,"url":null,"abstract":"The letter about the article “Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study” that discusses some points about methodology, outcome measures, and results.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":"31 1","pages":"2698811241276505"},"PeriodicalIF":4.5000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811241276505","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The letter about the article “Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study” that discusses some points about methodology, outcome measures, and results.
期刊介绍：
The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
